Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates

Infection and Immunity

Volumn 82, Issue 12, 2014, Pages 5049-5055

  Park, Saeyoung ^a,c   Gerber, Sabina ^b   Lee, Jean C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GlycoVaxyn AG   (Switzerland)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALUMINUM HYDROXIDE; ANTISERUM; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; CROSS REACTING ANTIBODY; EPITOPE; GLYCOCONJUGATE; OPSONIN; POLYSACCHARIDE VACCINE; STAPHYLOCOCCUS AUREUS SEROTYPE 5 CAPSULAR POLYSACCHARIDE VACCINE; STAPHYLOCOCCUS AUREUS SEROTYPE 8 CAPSULAR POLYSACCHARIDE VACCINE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONJUGATION; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SEROTYPE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; VACCINATION; ANIMAL; BACTEREMIA; BLOOD; CLASSIFICATION; DISEASE MODEL; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIAL VIABILITY; MICROBIOLOGY; RABBIT; SERUM BACTERICIDAL ACTIVITY;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BLOOD BACTERICIDAL ACTIVITY; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED ICR; MICROBIAL VIABILITY; OPSONIN PROTEINS; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; RABBITS; SEROGROUP; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINES, CONJUGATE;

EID: 84911384725     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02373-14     Document Type: Article

References (42)

1. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat. Rev. Microbiol. 12:49-62. http://dx.doi.org/10.1038/nrmicro3161.
2. Loughman JA, Fritz SA, Storch GA, Hunstad DA. 2009. Virulence gene expression in human community-acquired Staphylococcus aureus infection. J. Infect. Dis. 199:294-301. http://dx.doi.org/10.1086/595982.
3. O'Riordan K, Lee JC. 2004. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17:218-234. http://dx.doi.org/10.1128/CMR.17.1.218-234.2004.
4. Hochkeppel HK, Braun DG, Vischer W, Imm A, Sutter S, Staeubli U, Guggenheim R, Kaplan EL, Boutonnier A, Fournier JM. 1987. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J. Clin. Microbiol. 25:526-530.
5. Arbeit RD, Karakawa WW, Vann WF, Robbins JB. 1984. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2:85-91. http://dx.doi.org/10.1016/0732-8893(84)90002-6.
6. Thakker M, Park JS, Carey V, Lee JC. 1998. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun. 66:5183-5189.
7. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. 2005. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect. Immun. 73:3502-3511. http://dx.doi.org/10.1128/IAI.73.6.3502-3511.2005.
8. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC. 2006. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc. Natl. Acad. Sci. U. S. A. 103:10408-10413. http://dx.doi.org/10.1073/pnas.0508961103.
9. Nilsson IM, Lee JC, Bremell T, Rydén C, Tarkowski A. 1997. The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect. Immun. 65:4216-4221.
10. Portolés M, Kiser KB, Bhasin N, Chan KH, Lee JC. 2001. Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression. Infect. Immun. 69:917-923. http://dx.doi.org/10.1128/IAI.69.2.917-923.2001.
11. Jones C. 2005. Revised structures for the capsular polysaccharides from Staphylococcus aureus types 5 and 8, components of novel glycocon-jugate vaccines. Carbohydr. Res. 340:1097-1106. http://dx.doi.org/10.1016/j.carres.2005.02.001.
12. Melles DC, Taylor KL, Fattom AI, van Belkum A. 2008. Serotyping of Dutch Staphylococcus aureus strains from carriage and infection. FEMS Immunol. Med. Microbiol. 52:287-292. http://dx.doi.org/10.1111/j.1574-695X.2008.00376.x.
13. Karakawa WW, Fournier JM, Vann WF, Arbeit R, Schneerson RS, Robbins JB. 1985. Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J. Clin. Microbiol. 22:445-447.
14. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023-1032.
15. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, Braun M, Quebatte J, Gambillara V, Carranza P, Steffen M, Lee JC. 2014. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J. Infect. Dis. 209:1551-1561. http://dx.doi.org/10.1093/infdis/jit800.
16. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. 1997. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 65: 4146-4151.
17. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. 2008. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun. 76:5738-5744. http://dx.doi.org/10.1128/IAI.00874-08.
18. Lattar SM, Noto Llana M, Denoël P, Germain S, Buzzola FR, Lee JC, Sordelli DO. 2014. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect. Immun. 82:83-91. http://dx.doi.org/10.1128/IAI.01050-13.
19. Jansen WT, Snippe H. 2004. Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J. Med. Res. 119(Suppl):7-12.
20. Benaissa-Trouw B, Lefeber DJ, Kamerling JP, Vliegenthart JF, Kraaijeveld K, Snippe H. 2001. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect. Immun. 69:4698-4701. http://dx.doi.org/10.1128/IAI.69.7.4698-4701.2001.
21. Danieli E, Proietti D, Brogioni G, Romano MR, Cappelletti E, Tontini M, Berti F, Lay L, Costantino P, Adamo R. 2012. Synthesis of Staphylococcus aureus type 5 capsular polysaccharide repeating unit using novel L-FucNAc and D-FucNAc synthons and immunochemical evaluation. Bioorg. Med. Chem. 20:6403-6415. http://dx.doi.org/10.1016/j.bmc.2012.08.048.
22. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thöny-Meyer L. 2010. Production of glycoprotein vaccines in Escherichia coli. Microb. Cell. Fact. 9:61. http://dx.doi.org/10.1186/1475-2859-9-61.
23. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase; mode of action and antigenicity. J. Gen. Microbiol. 6:95-107. http://dx.doi.org/10.1099/00221287-6-1-2-95.
24. Bhasin N, Albus A, Michon F, Livolsi PJ, Park JS, Lee JC. 1998. Identification of a gene essential for O-acetylation of the Staphylococcus aureus type 5 capsular polysaccharide. Mol. Microbiol. 27:9-21. http://dx.doi.org/10.1046/j.1365-2958.1998.00646.x.
25. Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amézaga JM, Cooper D, Jansen KU, Anderson AS. 2013. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum. Vaccin. Immunother. 9:480-487. http://dx.doi.org/10.4161/hv.23223.
26. Fattom AI, Sarwar J, Basham L, Ennifar S, Naso R. 1998. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect. Immun. 66:4588-4592.
27. Tzianabos AO, Wang JY, Lee JC. 2001. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc. Natl. Acad. Sci. U. S. A. 98:9365-9370. http://dx.doi.org/10.1073/pnas.161175598.
28. Gray BM. 1979. ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes. J. Immunol. Methods 28:187-192. http://dx.doi.org/10.1016/0022-1759(79)90340-5.
29. Burton RL, Nahm MH. 2006. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13:1004-1009. http://dx.doi.org/10.1128/CVI.00112-06.
30. Sau S, Bhasin N, Wann ER, Lee JC, Foster TJ, Lee CY. 1997. The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology 143:2395-2405. http://dx.doi.org/10.1099/00221287-1 43-7-2395.
31. Dean CR, Franklund CV, Retief JD, Coyne MJ, Hatano K, Evans DJ, Pier GB, Goldberg JB. 1999. Characterization of the serogroup O11 O-antigen locus of Pseudomonas aeruginosa PA103. J. Bacteriol. 181:4275-4284.
32. Väkeväinen M, Eklund C, Eskola J, Käyhty H. 2001. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J. Infect. Dis. 184:789-793. http://dx.doi.org/10.1086/322984.
33. Park S, Parameswar AR, Demchenko AV, Nahm MH. 2009. Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups. Infect. Immun. 77: 3374-3379. http://dx.doi.org/10.1128/IAI.00319-09.
34. Szu SC, Li XR, Stone AL, Robbins JB. 1991. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59:4555-4561.
35. Fusco PC, Farley EK, Huang CH, Moore S, Michon F. 2007. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin. Vaccine Immunol. 14:577-584. http://dx.doi.org/10.1128/CVI.00009-07.
36. Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC. 2000. Structure activity studies on group C meningococcal polysaccharideprotein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 103:151-160.
37. Berry DS, Lynn F, Lee CH, Frasch CE, Bash MC. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70: 3707-3713. http://dx.doi.org/10.1128/IAI.70.7.3707-3713.2002.
38. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. 2013. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309:1368-1378. http://dx.doi.org/10.1001/jama.2013.3010.
39. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491-496. http://dx.doi.org/10.1056/NEJMoa011297.
40. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU. 2012. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum. Vaccin. Immunother. 8:1585-1594. http://dx.doi.org/10.4161/hv.21872.
41. Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB. 2012. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One 7:e46648. http://dx.doi.org/10.1371/journal.pone.0046648.
42. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, McNeely T. 2012. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum. Vaccin. Immunother. 8:336-346. http://dx.doi.org/10.4161/hv.18946.